Awakn has entered into a new partnership agreement with Nushama, one of New York’s leading ketamine-assisted therapy centres.
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...
Biotechnology company Lusaris Therapeutics – which has a lead programme focusing on DMT for treatment-resistant depression – has launched with its Series A financing of US$60...
Will Alberta’s new regulatory framework for the delivery of psychedelic therapies pave the way for their integration into the healthcare system, or will it create a...
Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...
Biopharmaceutical company, Ceruvia Lifesciences, has announced the appointment of Stephen Hurst and David Steinberg to its Board of Directors, effective immediately.
Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.
New data has revealed that a single 25mg dose of COMPASS Pathways’ COMP360 psilocybin in combination with psychological support had a significant impact in reducing symptoms...
On November 8, 2022, Colorado citizens will be casting their vote on the Natural Medicine Health Act 2022 which proposes to decriminalise and regulate the use...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...